Jaguar Animal Health Secures Debt Financing
The Company intends to use the loan proceeds to finance clinical activities, commercialization, and general working capital.
The Loan Facility has an initial term of approximately 36 months
“We are pleased to complete this fundraising to support ongoing clinical
activities for our potential drug candidates,” commented
For more information, please visit www.jaguaranimalhealth.com.
Certain statements in this press release constitute “forward-looking statements.” These include statements regarding the anticipated launch of Canaleviain early 2016 and the possible expansion of ongoing commercial opportunities with Neonorm. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.